Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MERCURY study of OriCAR-017 in relapsed/refractory multiple myeloma
CTR20232814Phase 2Active
- Sponsor
- OriCell Therapeutics
- Start
- Dec 2023
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Countries
- 1
01
Overview
A Phase 2 trial of oricar-017 in multiple myeloma (MM), sponsored by OriCell Therapeutics. Started Dec 2023; status: active.
02
Drugs
oricar-017
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on CTR20232814.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20232814.